WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced…
VYD222 has been generally well-tolerated at all dose levels, with no serious adverse events reported to dateAs predicted by pre-clinical…
Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into…
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively…
Company Recently Reached Agreement with FDA on Design of Trial Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, June 22, 2023…
Media ReleaseCOPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody,…
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or…
HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company…
Large trial in adults comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza®…
- Enrollment ongoing at multiple sites in the US, Europe, and Asia - - Multifaceted activity of serotonin-dopamine stabilizer brilaroxazine…